Home › Mild Cognitive Impairment › NCT06058234
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD. Exclusion Criteria: * none
About the study
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
What is being tested
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (drug)
Sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group · Participants: 8,680 · Started: Jul 6, 2023
Contact the study team
- CMS CAG · Phone: 410-786-2281
Official record on ClinicalTrials.gov — NCT06058234
Locations in the U.S.
| Maryland | Centers for Medicare and Medicaid Services, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.